| 102.26 -0.06 (-0.06%) | 03-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 121.97 | 1-year : | 127.17 |
| Resists | First : | 104.43 | Second : | 108.87 |
| Pivot price | 102.23 |
|||
| Supports | First : | 97.23 | Second : | 80.9 |
| MAs | MA(5) : | 101.35 |
MA(20) : | 102.16  |
| MA(100) : | 102.05 |
MA(250) : | 86.84 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 39.5 |
D(3) : | 35.3 |
| RSI | RSI(14): 49.5 |
|||
| 52-week | High : | 113.01 | Low : | 55.53 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NUVL ] has closed below upper band by 49.7%. Bollinger Bands are 48.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 103.98 - 104.49 | 104.49 - 104.99 |
| Low: | 99.75 - 100.38 | 100.38 - 101.01 |
| Close: | 101.08 - 102.09 | 102.09 - 103.09 |
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Sun, 08 Mar 2026
American Century Companies Inc. Sells 11,767 Shares of Nuvalent, Inc. $NUVL - MarketBeat
Fri, 27 Feb 2026
Does Nuvalent (NUVL) Have the Potential to Rally 37.26% as Wall Street Analysts Expect? - Yahoo Finance
Thu, 05 Feb 2026
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - PR Newswire
Wed, 10 Dec 2025
Nuvalent Appoints Ron Squarer to Board of Directors - PR Newswire
Mon, 08 Dec 2025
Nuvalent, Inc. (NUVL) is a Buy On lung Cancer Treatment Prospects - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 73 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 2.6 (%) |
| Held by Institutions | 111.2 (%) |
| Shares Short | 5,680 (K) |
| Shares Short P.Month | 5,750 (K) |
| EPS | -5.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 15.94 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.3 % |
| Return on Equity (ttm) | -36.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -275 (M) |
| Levered Free Cash Flow | -142 (M) |
| PE Ratio | -17.49 |
| PEG Ratio | 0 |
| Price to Book value | 6.41 |
| Price to Sales | 0 |
| Price to Cash Flow | -27.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|